Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q8IZC6
UPID:
CORA1_HUMAN
Alternative names:
-
Alternative UPACC:
Q8IZC6; Q66K43; Q96JF7
Background:
The Collagen alpha-1(XXVII) chain plays a crucial role in the calcification of cartilage and the transition of cartilage to bone. This protein is essential for proper skeletal development and maintenance.
Therapeutic significance:
Steel syndrome, characterized by dislocated hips, radial heads, fusion of carpal bones, and more, is linked to variants affecting this gene. Understanding the role of Collagen alpha-1(XXVII) chain could lead to targeted therapies for this syndrome.